Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Carcinoma Metastatic in the Bone: early-phase trial registry
A small indexed set (7 trials) with no open enrollment listed right now.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · none currently recruiting · #2,497 of 28,707 conditions by registered trial count
Prostate Carcinoma Metastatic in the Bone: 7 US clinical trials tracked, none currently recruiting.
Prostate Carcinoma Metastatic in the Bone is the subject of 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition prostate-carcinoma-metastatic-in-the-bone
OPEN 0 | RECR 0% | LATE 0 | EARLY 7 | RANK #2497 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Prostate Carcinoma Metastatic in the Bone has no open enrollment in this registry pull (7 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Carcinoma Metastatic in the Bone on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Carcinoma Metastatic in the Bone is recruiting below its size-band peers.
0 of 7 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Prostate Carcinoma Metastatic in the Bone research.
M.D. Anderson Cancer Center accounts for 3 of 7 trials (42.9%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Prostate Carcinoma Metastatic in the Bone trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
Prostate Carcinoma Metastatic in the Bone research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
7 total, page 1 of 1
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
ECOG-ACRIN Cancer Research Group
NCT03419234
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT03217747
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
M.D. Anderson Cancer Center
NCT03821792
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
NCT02713269
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
University of Southern California
NCT03344211
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
NCT03582475
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
University of Washington
NCT02598895
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Carcinoma Metastatic in the Bone records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Carcinoma Metastatic in the Bone trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Carcinoma Metastatic in the Bone page
7 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Prostate Carcinoma Metastatic in the Bone trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- M.D. Anderson Cancer Center sponsors the most Prostate Carcinoma Metastatic in the Bone trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Carcinoma Metastatic in the Bone condition card totals 7 registered trials; most-linked intervention Abiraterone Acetate; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.